Taft attorneys Andrew M. Alul and Richard T. Ruzich will be featured presenters at the American Conference Institute’s Paragraph IV Disputes Conference, to be held April 25-26 in New York City. Ruzich will participate on the panel “On Sale Bar in a Hatch-Waxman Setting: Analyzing Patent Impediments Caused by Contract Manufacturing and Its Impact on Pharmaceutical Product Market Access.” Alul will speak during the session “In the Limelight: Examining Lily v. Teva and its Larger Implications for Divided and Induced Infringement in a Hatch-Waxman Setting.”

The event is known as the pharmaceutical industry's leading forum on Hatch-Waxman litigation. Taft will sponsor the breakfast on April 26. To register or learn more about this event, click here.

Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney and frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilars sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development and through to market entry, including at-risk launches.

Alul focuses his practice primarily on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA). He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.